Key result
Uptake of heart failure therapies improved from 1999 to 2007 (ACEI/ARB from 46% to 64%, β-blockers from 12% to 41%), with no consistent socioeconomic gradients in treatment or case fatality.
Why the study?
Are there socioeconomic gradients in the uptake of key medical therapies and outcomes in patients with heart failure?
Population
13,330 patients with heart failure in 1999 and 2007 from the General Practice Research Database in England
Design
Cross-sectional
Authors
Loading...
Equity in HF therapy uptake supports primary care models; extends 1999-2007 trends but leaves persistence and generalizability open.
Cross-Sectional (n=13,330)
Yes
Are there socioeconomic gradients in the uptake of key medical therapies and outcomes in patients with heart failure?
Socioeconomic gradients in heart failure incidence and prevalence are reducing, and the delivery of key medical therapies is generally equitable across socioeconomic groups in England.
Hawkins et al. (2012) conducted a cross-sectional in Heart failure (n=13,330). Medical therapies (ACE inhibitors/ARBs, β-blockers, spironolactone) vs. Socioeconomic circumstances was evaluated on Uptake of key medical therapies stratified by socioeconomic circumstances. Uptake of heart failure therapies improved from 1999 to 2007 (ACEI/ARB from 46% to 64%, β-blockers from 12% to 41%), with no consistent socioeconomic gradients in treatment or case fatality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: